Figure 6.

A. Overall survival curve of the 84 patients included in the study. The median overall survival has not been reached, with a maximum follow-up of 146.53 months; B. Overall survival curve according to Ann Arbor Staging. The median overall survival in clinical stage I/II group has not been reached, while in the III/IV group was 24.27 months (log-rank, p=0.0256); C. Overall survival curve according to the International Prognostic Index (IPI). The median overall survival in the low and intermediate IPI groups was not achieved and was 8.47 months in the high IPI group (log-rank, p=0.0236; IPI 0-1: low; IPI 2-3: intermediate; IPI 4-5: high); D. Overall survival curve according to MVD (automated counting (CD34+/100μm²). The median overall survival in groups of quartiles I/II and quartiles III/IV has not been reached (log-rank, p=0.0363); E. Overall survival curve of the patients according to stromal signature. The median overall survival in the stromal-1 and stromal-2 groups was not reached (log-rank, p=0.6157).